Kenvue Inc.
KVUE
Rank in Stocks
#664
Kenvue Inc. functions as a global leader in the consumer health sector. The... Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Share Price
$19.21
Market Cap
$36.89B
Change (1 day)
1.78%
Change (1 year)
28.38%
Country
US
Trade Kenvue Inc. (KVUE)
Category
Consumer Defensive
Earnings for Kenvue Inc. (KVUE)
Earnings in Jun 2026 TTM: $2.22B
According to Kenvue Inc. latest financial reports the company's current earnings are $2.22B. In 2023 the company made an earning of $2.19B, a decrease compared to its 2022 earnings that were of $2.64B. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Kenvue Inc. from 2019 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $2.22B | 57.10% |
| 2024 | $1.42B | -35.39% |
| 2023 | $2.19B | -16.95% |
| 2022 | $2.64B | -9.85% |
| 2021 | $2.93B | -387.89% |
| 2020 | $-1.02B | -147.92% |
| 2019 | $2.12B | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $20.38B | 816.64% |
US
|
|
| $9.83B | 342.03% |
FR
|
|
| $2.94B | 32.30% |
US
|
|
| $1.55B | -30.27% |
IN
|
|
| $517.00M | -76.74% |
US
|
